533 related articles for article (PubMed ID: 34792124)
1. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
3. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.
Dhingra NK; Mistry N; Puar P; Verma R; Anker S; Mazer CD; Verma S
ESC Heart Fail; 2021 Dec; 8(6):4693-4700. PubMed ID: 34623032
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies.
Carluccio E; Biagioli P; Reboldi G; Mengoni A; Lauciello R; Zuchi C; D'Addario S; Bardelli G; Ambrosio G
Cardiovasc Diabetol; 2023 Sep; 22(1):235. PubMed ID: 37660005
[TBL] [Abstract][Full Text] [Related]
6. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
[TBL] [Abstract][Full Text] [Related]
9. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
10. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.
Li M; Yi T; Fan F; Qiu L; Wang Z; Weng H; Ma W; Zhang Y; Huo Y
Cardiovasc Diabetol; 2022 Jul; 21(1):139. PubMed ID: 35879763
[TBL] [Abstract][Full Text] [Related]
12. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
[TBL] [Abstract][Full Text] [Related]
14. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
Fan G; Guo DL
Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
17. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Usman MS; Januzzi JL; Anker SD; Salman A; Parikh PB; Adamo M; Filippatos G; Khan MS; Lala A; Verma S; Metra M; Butler J
Eur J Heart Fail; 2024 Feb; 26(2):373-382. PubMed ID: 38235936
[TBL] [Abstract][Full Text] [Related]
18. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
Gonzalez J; Dave CV
BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
